Quality of Life (QoL) in schizophrenia patients on Abilify Maintena (Aripiprazole) versus treatment with other atypical anti-psychotics (oral or depot) in a private mental health setting: a pilot randomized controlled trial.

Trial Profile

Quality of Life (QoL) in schizophrenia patients on Abilify Maintena (Aripiprazole) versus treatment with other atypical anti-psychotics (oral or depot) in a private mental health setting: a pilot randomized controlled trial.

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 23 Mar 2018

At a glance

  • Drugs Aripiprazole (Primary)
  • Indications Schizophrenia
  • Focus Therapeutic Use
  • Most Recent Events

    • 20 Mar 2018 Planned End Date changed from 30 Sep 2018 to 31 Dec 2018.
    • 20 Mar 2018 Status changed from not yet recruiting to recruiting.
    • 09 Feb 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top